Cargando…

Expanded and activated allogeneic NK cells are cytotoxic against B-chronic lymphocytic leukemia (B-CLL) cells with sporadic cases of resistance

Adoptive transfer of allogeneic natural killer (NK) cells is becoming a credible immunotherapy for hematological malignancies. In the present work, using an optimized expansion/activation protocol of human NK cells, we generate expanded NK cells (eNK) with increased expression of CD56 and NKp44, whi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Calvo, Tania, Reina-Ortiz, Chantal, Giraldos, David, Gascón, María, Woods, Daniel, Asenjo, Judit, Marco-Brualla, Joaquín, Azaceta, Gemma, Izquierdo, Isabel, Palomera, Luis, Sánchez-Martínez, Diego, Marzo, Isabel, Naval, Javier, Vilches, Carlos, Villalba, Martín, Anel, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7655821/ https://www.ncbi.nlm.nih.gov/pubmed/33173077 http://dx.doi.org/10.1038/s41598-020-76051-z

Ejemplares similares

Harnessing the Potential of NK Cell-Based Immunotherapies against Multiple Myeloma
por: Reina-Ortiz, Chantal, et al.
Publicado: (2022)

Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients
por: Reina-Ortiz, Chantal, et al.
Publicado: (2020)

Activated Allogeneic NK Cells Preferentially Kill Poor Prognosis B-Cell Chronic Lymphocytic Leukemia Cells
por: Sánchez-Martínez, Diego, et al.
Publicado: (2016)

Ecto-calreticulin expression in multiple myeloma correlates with a failed anti-tumoral immune response and bad prognosis
por: Serrano Del Valle, Alfonso, et al.
Publicado: (2022)

Immunogenic Cell Death and Immunotherapy of Multiple Myeloma
por: Serrano-del Valle, Alfonso, et al.
Publicado: (2019)

Response: Commentary: Immunogenic Cell Death and Immunotherapy of Multiple Myeloma
por: Serrano Del Valle, Alfonso, et al.
Publicado: (2019)

Study of the Bcl-2 Interactome by BiFC Reveals Differences in the Activation Mechanism of Bax and Bak
por: Gonzalo, Óscar, et al.
Publicado: (2023)

Conjugation of the 9-kDa Isoform of Granulysin with Liposomes Potentiates Its Cytotoxicity
por: Soler-Agesta, Ruth, et al.
Publicado: (2022)

Dynamic Changes in miRNA Expression during the Generation of Expanded and Activated NK Cells
por: Reina-Ortiz, Chantal, et al.
Publicado: (2023)

NF-kB and the CLL microenvironment
por: O’Donnell, Alice, et al.
Publicado: (2023)

Hemizygous amplification and complete Sanger sequencing of HLA‐C*07:37:01:02 from a South European Caucasoid
por: Asenjo, Judit, et al.
Publicado: (2020)

Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumors
por: Sanchez-Martinez, Diego, et al.
Publicado: (2018)

Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies
por: Pflug, Natali, et al.
Publicado: (2021)

The metabolism of cells regulates their sensitivity to NK cells depending on p53 status
por: Belkahla, Sana, et al.
Publicado: (2022)

VEGF and bFGF gene polymorphisms in Polish patients with B-CLL
por: Wróbel, Tomasz, et al.
Publicado: (2013)

The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL
por: Parikh, Sameer A., et al.
Publicado: (2021)

Factors involved in CLL pathogenesis and cell survival are disrupted by differentiation of CLL B-cells into antibody-secreting cells
por: Ghamlouch, Hussein, et al.
Publicado: (2015)

BTLA Expression in CLL: Epigenetic Regulation and Impact on CLL B Cell Proliferation and Ability to IL-4 Production
por: Karabon, Lidia, et al.
Publicado: (2021)

Apoptotic pathways are selectively activated by granzyme A and/or granzyme B in CTL-mediated target cell lysis
por: Pardo, Julián, et al.
Publicado: (2004)

Metformin sensitizes leukemic cells to cytotoxic lymphocytes by increasing expression of intercellular adhesion molecule-1 (ICAM-1)
por: Allende-Vega, Nerea, et al.
Publicado: (2022)

Clonal expansion in B-CLL: Fungal drivers or self-service?
por: Greaves, Mel
Publicado: (2013)

Boosting BNT162b2 vaccine efficacy in CLL
por: Bhat, Seema A., et al.
Publicado: (2022)

Spatial organization and early signaling of the B-cell receptor in CLL
por: Shorer Arbel, Yamit, et al.
Publicado: (2022)

Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
por: Heipertz, Erica L., et al.
Publicado: (2021)

Function of B-Cell CLL/Lymphoma 11B in Glial Progenitor Proliferation and Oligodendrocyte Maturation
por: Wang, Chih-Yen, et al.
Publicado: (2018)

Rituximab mechanisms of action in B-CLL: a new piece of the puzzle
por: Watier, Hervé
Publicado: (2018)

Progressive Multifocal Leukoencephalopathy in B-CLL Successfully Treated With Venetoclax and Pembrolizumab
por: Olivieri, Jacopo, et al.
Publicado: (2022)

Complete genomic characterization of a new KLRC2 allele, NKG2C*03
por: Asenjo, Judit, et al.
Publicado: (2021)

DNA damage response and evasion from immunosurveillance in CLL: new options for NK cell-based immunotherapies
por: Shatnyeva, Olga M., et al.
Publicado: (2015)

Tafasitamab mediates killing of B-cell non-Hodgkin’s lymphoma in combination with γδ T cell or allogeneic NK cell therapy
por: Her, Jung Hyun, et al.
Publicado: (2022)

The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells
por: Saulep-Easton, Damien, et al.
Publicado: (2015)

A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL
por: Jain, Nitin, et al.
Publicado: (2022)

Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
por: Montillo, Marco, et al.
Publicado: (2008)

Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLL
por: Efremov, Dimitar G., et al.
Publicado: (2012)

Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. Krohem B-Cll 2017
por: Jakšić, Branimir, et al.
Publicado: (2018)

XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression
por: Fisher, Jack G., et al.
Publicado: (2023)

HLA specificities are associated with prognosis in IGHV-mutated CLL-like high-count monoclonal B cell lymphocytosis
por: García-Álvarez, María, et al.
Publicado: (2017)

DR5 Up-Regulation Induced by Dichloroacetate Sensitizes Tumor Cells to Lipid Nanoparticles Decorated with TRAIL
por: Marco-Brualla, Joaquín, et al.
Publicado: (2023)

The survival decrease in gastric cancer is associated with the methylation of B-cell CLL/lymphoma 6 member B promoter
por: Deng, Jingyu, et al.
Publicado: (2014)

Donor Vδ1(+) γδ T cells expand after allogeneic hematopoietic stem cell transplantation and show reactivity against CMV-infected cells but not against progressing B-CLL
por: Prinz, Immo, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_2mjq3v15m7jfbhjfo5jmdtp2sd